Current trends in peanut allergy immunotherapy: a review
Peanut allergy (PA) poses significant clinical challenges due to its potentially life-threatening nature and increasing prevalence, particularly in children. Strict avoidance is difficult due to the widespread presence of peanuts in various foods, leading to high rates of accidental exposure. Tradit...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2024-04-01
|
| Series: | Alergologia Polska |
| Subjects: | |
| Online Access: | https://www.termedia.pl/Current-trends-in-peanut-allergy-immunotherapy-a-review,123,53965,1,1.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832584885551759360 |
|---|---|
| author | Klementyna Łyżwa Anna Krupa-Łaska Joanna Zielińska Marek Kulus Katarzyna Grzela |
| author_facet | Klementyna Łyżwa Anna Krupa-Łaska Joanna Zielińska Marek Kulus Katarzyna Grzela |
| author_sort | Klementyna Łyżwa |
| collection | DOAJ |
| description | Peanut allergy (PA) poses significant clinical challenges due to its potentially life-threatening nature and increasing prevalence, particularly in children. Strict avoidance is difficult due to the widespread presence of peanuts in various foods, leading to high rates of accidental exposure. Traditional management includes education, avoidance, and rescue medication. Recent advances in immunotherapy offer promising avenues for the management of PA. Various methods of immunotherapy have been investigated, including oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT). Immunotherapy is associated with challenges such as adverse effects, the risk of anaphylaxis, and the long-term persistence of tolerance. Combining immunotherapy with adjuvants such as omalizumab and dupilumab or probiotics is promising, but it raises questions about sustained efficacy and patient response after treatment discontinuation. In addition, the translation of clinical trial results into real-world settings remains a critical issue, as shown by low participation rates in immunotherapy programs. Immunotherapy for peanut allergy has the potential to be a game-changer in the treatment of peanut allergies. However, it is important to note that this treatment is not without its challenges. Further research, collaboration between clinicians and researchers, and addressing patient concerns are needed to establish immunotherapy as a safe and effective treatment option for individuals with peanut allergy. |
| format | Article |
| id | doaj-art-b95098150a524a12934e6f8244eb32a3 |
| institution | Kabale University |
| issn | 2353-3854 2391-6052 |
| language | English |
| publishDate | 2024-04-01 |
| publisher | Termedia Publishing House |
| record_format | Article |
| series | Alergologia Polska |
| spelling | doaj-art-b95098150a524a12934e6f8244eb32a32025-01-27T10:34:44ZengTermedia Publishing HouseAlergologia Polska2353-38542391-60522024-04-0111215416210.5114/pja.2024.13891953965Current trends in peanut allergy immunotherapy: a reviewKlementyna ŁyżwaAnna Krupa-ŁaskaJoanna ZielińskaMarek KulusKatarzyna GrzelaPeanut allergy (PA) poses significant clinical challenges due to its potentially life-threatening nature and increasing prevalence, particularly in children. Strict avoidance is difficult due to the widespread presence of peanuts in various foods, leading to high rates of accidental exposure. Traditional management includes education, avoidance, and rescue medication. Recent advances in immunotherapy offer promising avenues for the management of PA. Various methods of immunotherapy have been investigated, including oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT). Immunotherapy is associated with challenges such as adverse effects, the risk of anaphylaxis, and the long-term persistence of tolerance. Combining immunotherapy with adjuvants such as omalizumab and dupilumab or probiotics is promising, but it raises questions about sustained efficacy and patient response after treatment discontinuation. In addition, the translation of clinical trial results into real-world settings remains a critical issue, as shown by low participation rates in immunotherapy programs. Immunotherapy for peanut allergy has the potential to be a game-changer in the treatment of peanut allergies. However, it is important to note that this treatment is not without its challenges. Further research, collaboration between clinicians and researchers, and addressing patient concerns are needed to establish immunotherapy as a safe and effective treatment option for individuals with peanut allergy.https://www.termedia.pl/Current-trends-in-peanut-allergy-immunotherapy-a-review,123,53965,1,1.htmlfood allergy peanut allergy food immunotherapy oral immunotherapy children |
| spellingShingle | Klementyna Łyżwa Anna Krupa-Łaska Joanna Zielińska Marek Kulus Katarzyna Grzela Current trends in peanut allergy immunotherapy: a review Alergologia Polska food allergy peanut allergy food immunotherapy oral immunotherapy children |
| title | Current trends in peanut allergy immunotherapy: a review |
| title_full | Current trends in peanut allergy immunotherapy: a review |
| title_fullStr | Current trends in peanut allergy immunotherapy: a review |
| title_full_unstemmed | Current trends in peanut allergy immunotherapy: a review |
| title_short | Current trends in peanut allergy immunotherapy: a review |
| title_sort | current trends in peanut allergy immunotherapy a review |
| topic | food allergy peanut allergy food immunotherapy oral immunotherapy children |
| url | https://www.termedia.pl/Current-trends-in-peanut-allergy-immunotherapy-a-review,123,53965,1,1.html |
| work_keys_str_mv | AT klementynałyzwa currenttrendsinpeanutallergyimmunotherapyareview AT annakrupałaska currenttrendsinpeanutallergyimmunotherapyareview AT joannazielinska currenttrendsinpeanutallergyimmunotherapyareview AT marekkulus currenttrendsinpeanutallergyimmunotherapyareview AT katarzynagrzela currenttrendsinpeanutallergyimmunotherapyareview |